Liver Cirrhosis
Conditions
Interventions
This is a two-arm, randomized, controlled clinical trial without cagamete. Experimental group: 12 patients with an ultrasound finding of moderate to severe hepatic steatosis will receive a needle biop
Sponsors
Instituto para O Desenvolvimento da Educação Ltda.
Instituto para O Desenvolvimento da Educação Ltda.
Eligibility
Inclusion criteria
Inclusion criteria: Patients with moderate to severe hepatic steatosis, submitted to abdominal laparoscopic surgery for another underlying disease; Patients who needed a liver biopsy for etiological confirmation or staging of disease activity
Exclusion criteria
Exclusion criteria: Refusal to participate in the study: Patients diagnosed with hepatocellular carcinoma (HCC) AND The following risk factors: Patients with INR > 1.8 and/or platelets < 70,000/mm3; Patients diagnosed with hepatocellular carcinoma (HCC); Patients with coagulopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome: 44% reduction in painful symptoms and bleeding.;Outcome reached: 44% reduction in painful symptoms and bleeding. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes planned. | — |
Countries
Brazil
Contacts
Public ContactAlexandre Mano
IPADE - Instituto para o Desenvolvimento da Educação Ltda.
Outcome results
None listed